Filtered By:
Drug: Zivast
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 875 results found since Jan 2013.
Effect of atorvastatin on expression of TLR4 and NF- κB in stroke rats and its protective effect on brain.
CONCLUSIONS: Atorvastatin can effectively reduce the expression of TLR4 and NF-κB in brain tissue of stroke rats, and has a certain protective effect on cerebral nerve function, which is expected to be the first choice for stroke treatment in the future.
PMID: 33155240 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - November 10, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis
This study also provided evidence of biomarkers involved in hemorrhage stroke and improved understanding of the effects of HMG-COA reductase inhibition on vascular permeability and cerebral hemorrhage.
Source: Frontiers in Pharmacology - October 1, 2020 Category: Drugs & Pharmacology Source Type: research
Effects of High Dose of Atorvastatin for Preventing Periprocedural Ischemic Brain Damage in Patients Undergoing Carotid Artery Stenting (PICAS) in China: A Randomized Controlled Clinical Trial
This study is the first to assess whether high-dose atorvastatin treatment is capable of reducing the incidence of perioperative cerebral ischemic injury in patients of Chinese ethnicity undergoing CAS. These results will offer evidence regarding which statin treatment regimens are more appropriate when treating Chinese patients undergoing CAS in an effort to minimize their risk of any perioperative cerebral ischemic injury.Trial Registration:ClinicalTrials.gov NCT03079115; registered March 14, 2017.
Source: Frontiers in Neurology - August 24, 2020 Category: Neurology Source Type: research
Therapeutic Effects of Iron Chelation in Atorvastatin-Induced Intracranial Hemorrhage of Zebrafish Larvae
Intracranial hemorrhage (ICH) acutely and severely damages brain function.1,2 The prognosis of ICH is poor due to the drastic and rapid progression of its pathology, and the lack of effective treatments presents a significant unmet clinical need. Therefore, novel therapeutic agents for ICH have the potential to significantly improve clinical outcomes. The collagenase-induced rodent ICH model is the most commonly used experimental ICH model.3 However, detailed live imaging of hematoma development in rodent models is inherently limited, as rodents are opaque.
Source: Journal of Stroke and Cerebrovascular Diseases - August 13, 2020 Category: Neurology Authors: Shinsuke Nakamura, Yuichi Saito, Takumi Gouda, Takahiko Imai, Masamitsu Shimazawa, Yuhei Nishimura, Hideaki Hara Source Type: research
SPARCL: Atorvastatin Stroke Benefit Reinforced in New Analysis SPARCL: Atorvastatin Stroke Benefit Reinforced in New Analysis
A new analysis of the SPARCL trial has shown that the total number of vascular events prevented with atorvastatin was more than twice the number of first events prevented.Medscape Medical News
Source: Medscape Cardiology Headlines - March 23, 2020 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
Temporal Trends and Patient Characteristics Associated With Drug Utilisation After First-Ever Stroke: Insights From Chronic Disease Registry Data in Singapore.
CONCLUSION: This study reveals changes in prescription behaviour over time in a multiethnic Asian population with first-ever stroke. Patient characteristics including younger age, Malay ethnicity and certain comorbidities (i.e. hyperlipidaemia, atrial fibrillation) were associated with the combined use of all 3 guideline medications among ischaemic stroke patients.
PMID: 32301477 [PubMed - in process]
Source: Ann Acad Med Singapo... - February 29, 2020 Category: General Medicine Authors: Yeo SH, Toh MPH, Lee SH, Seet RC, Wong LY, Yau WP Tags: Ann Acad Med Singapore Source Type: research
Error in USPSTF Report on Statin Use
The 2016 review for the US Preventive Services Task Force on statins for prevention of cardiovascular disease in adults had errors in the analysis of statins vs placebo and cardiovascular mortality. For the JUPITER trial, we interpreted “MI, stroke or cardiovascular death” as reported in the main trial publication as “myocardial death, stroke death, or cardiovascular death,” when it meant “nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death.” Therefore, the analysis erroneously included nonfatal myo cardial infarction and stroke events (83/8901 vs 157/8901 in the rosuvastatin vs placebo gro...
Source: JAMA - February 18, 2020 Category: General Medicine Source Type: research
Effect of high-dose strong statin for preventing periprocedural ischemic complications of carotid artery stenting
This study assessed the safety and usefulness of pretreatment using a high-dose strong statin (HDSS) to reduce the periprocedural ischemic complications of CAS. We analyzed 117 carotid lesions treated by CAS that were evaluated with magnetic resonance imaging (MRI) within 48 h after the procedure. For 67 lesions, an HDSS (rosuvastatin 20 mg or atorvastatin 40 mg daily) were prescribed from at least 14 days before CAS to at least 14 days after procedure (HDSS group). Clinical and angiographic data, as well as in-hospital outcomes, of the HDSS group were retrospecti vely compared with 50 lesions with conventional treat...
Source: Heart and Vessels - January 9, 2020 Category: Cardiology Source Type: research
Statin Therapy in Ischemic Stroke Models: A Meta-Analysis
AbstractStatins, drugs known for lipid lowering capabilities and reduction of cardiovascular disease, have demonstrated neuroprotective effects following ischemic stroke in retrospective clinical and animal studies. However, dosing (methods, time, type of statin, and quantity) varies across studies, limiting the clinical applicability of these findings. Furthermore, a comprehensive review of statins in edema and blood-brain barrier (BBB) breakdown is needed to provide insight on diverse, less explored neuroprotective effects. In the present study, we conduct a meta-analysis of publications evaluating statin administration ...
Source: Translational Stroke Research - December 1, 2019 Category: Neurology Source Type: research
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk
AbstractPurpose of ReviewTo review randomized interventional clinical and imaging trials that support lower targeted atherogenic lipoprotein cholesterol goals in “extreme” and “very high” atherosclerotic cardiovascular disease (ASCVD) risk settings. Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of the fundamental atherogenic ap olipoprotein B-associated lipoprotein cholesterol particles [i.e., triglyceride-rich lipoprotein remnant cholesterol, low-density lipoprotein cholesterol (LDL-C), and ...
Source: Current Diabetes Reports - November 20, 2019 Category: Endocrinology Source Type: research
Letter to the editor concerning coenzyme Q10 supplementation improves acute outcomes of stroke in rats pretreated with atorvastatin
.
Source: Nutritional Neuroscience - August 27, 2019 Category: Nutrition Authors: Masoud Soheili Mahmoud Salami Source Type: research
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research
Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
Publication date: Available online 9 August 2019Source: American Heart JournalAuthor(s): Kausik K. Ray, Stephen J. Nicholls, Henry Ginsberg, Jan O. Johansson, Kamyar Kalantar-Zadeh, Ewelina Kulikowski, Peter P. Toth, Norman Wong, Jeffrey L. Cummings, Michael Sweeney, Gregory G. SchwartzAbstractBackgroundAfter an acute coronary syndrome (ACS), patients with diabetes remain at high risk for additional cardiovascular events despite use of current therapies. Bromodomain and extra-terminal (BET) proteins are epigenetic modulators of inflammation, thrombogenesis, and lipoprotein metabolism implicated in atherothrombosis. The BET...
Source: American Heart Journal - August 9, 2019 Category: Cardiology Source Type: research
Safety and Efficacy of the C-117 Formula for Vulnerable Carotid Artery Plaques (Spchim): A Randomized Double-Blind Controlled Pilot Study.
Conclusion: The C-117 formula may be antiatherosclerotic by strengthening statins to reduce the low-density lipoprotein levels and reducing the carotid plaque Crouse scores. Clinical trials with large sample sizes, long-term interventions, and follow-up are needed to investigate the efficacy of the C-117 formula.
Clinical Trials Registration: This trial is registered with clinicaltrials.gov identifier: NCT03072225 (registered retrospectively on 1st March 2017).
PMID: 31391862 [PubMed]
Source: Evidence-based Complementary and Alternative Medicine - August 9, 2019 Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
